Optimal combination secondary prevention drug treatment and stroke outcomes

Neurology

Volumn 84, Issue 1, 2015, Pages 50-56

  Park, Jong Ho ^a   Ovbiagele, Bruce ^a,b  

^a Seonam University of Medicine Myongji Hospital   (South Korea)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS AFFECTING LIPID METABOLISM; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT;

ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; EVIDENCE BASED PRACTICE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY PREVENTION; STROKE PATIENT; SYSTOLIC BLOOD PRESSURE; ADULT; AGED; COMBINATION DRUG THERAPY; FEMALE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; STANDARDS; STROKE; TREATMENT OUTCOME;

ADULT; AGED; ANTICOAGULANTS; ANTIHYPERTENSIVE AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; SECONDARY PREVENTION; STROKE; TREATMENT OUTCOME;

EID: 84925962262     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001099     Document Type: Article

References (24)

1. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014;45:2160-2236.
2. Hall MJ, Levant S, DeFrances CJ. Hospitalization for stroke in US hospitals, 1989-2009. NCHS Data Brief 2012;95:1-8.
3. Rosengren A, Giang KW, Lappas G, Jern C, Toren K, Bjorck L. Twenty-four-year trends in the incidence of ischemic stroke in Sweden from 1987 to 2010. Stroke 2013;44:2388-2393.
4. Wang Y, Rudd AG, Wolfe CD. Trends and survival between ethnic groups after stroke: the South London Stroke Register. Stroke 2013;44:380-387.
5. Ovbiagele B. National sex-specific trends in hospital-based stroke rates. J Stroke Cerebrovasc Dis 2011;20:537-540.
6. Gu Q, Burt VL, Dillon CF, Yoon S. Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health and Nutrition Examination Survey, 2001 to 2010. Circulation 2012;126:2105-2114.
7. Lackland DT, Roccella EJ, Deutsch AF, et al. Factors influencing the decline in stroke mortality: A statement from the American Heart Association/American Stroke Association. Stroke 2014;45:315-353.
8. Ovbiagele B, Goldstein LB, Higashida RT, et al. Forecasting the future of stroke in the United States: A policy statement from the American Heart Association and American Stroke Association. Stroke 2013;44:2361-2375.
9. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419.
10. Combination Pharmacotherapy and Public Health Research Working Group. Combination pharmacotherapy for cardiovascular disease. Ann Intern Med 2005;143:593-599.
11. Lonn E, Bosch J, Teo KK, Pais P, Xavier D, Yusuf S. The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. Circulation 2010;122:2078-2088.
12. Mukherjee D, Fang J, Chetcuti S, Moscucci M, Kline-Rogers E, Eagle KA. Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes. Circulation 2004;109:745-749.
13. Danchin N, Cambou JP, Hanania G, et al. Impact of combined secondary prevention therapy after myocardial infarction: data from a nationwide French registry. Am Heart J 2005;150:1147-1153.
14. Yan AT, Yan RT, Tan M, et al. Optimal medical therapy at discharge in patients with acute coronary syndromes: temporal changes, characteristics, and 1-year outcome. Am Heart J 2007;154:1108-1115.
15. Bramlage P, Messer C, Bitterlich N, et al. The effect of optimal medical therapy on 1-year mortality after acute myocardial infarction. Heart 2010;96:604-609.
16. Bejot Y, Zeller M, Lorgis L, et al. Secondary prevention in patients with vascular disease: A population based study on the underuse of recommended medications. J Neurol Neurosurg Psychiatry 2013;84:348-353.
17. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004;291:565-575.
18. Bushnell CD, Olson DM, Zhao X, et al. Secondary preventive medication persistence and adherence 1 year after stroke. Neurology 2011;77:1182-1190.
19. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: A systematic review. Stroke 2003;34: 2741-2748.
20. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6, 105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-1041.
21. Amarenco P, Bogousslavsky J, Callahan A III, et al. Highdose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549-559.
22. Fox KA, Dabbous OH, Goldberg RJ, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ 2006;333:1091.
23. Rothwell PM, Howard SC, Dolan E, et al. Effects of beta blockers and calcium-channel blockers on withinindividual variability in blood pressure and risk of stroke. Lancet Neurol 2010;9:469-480.
24. Mukherjee D, Fang J, Kline-Rogers E, Otten R, Eagle KA. Impact of combination evidence based medical treatment in patients with acute coronary syndromes in various TIMI risk groups. Heart 2005;91:381-382.